Article
Obstetrics & Gynecology
M. P. Velez, H. Richardson, N. N. Baxter, Chad McClintock, E. Greenblatt, R. Barr, M. Green
Summary: Female adolescents and young adults with breast, hematological, thyroid and melanoma cancer have a higher risk of subsequent infertility diagnosis compared to AYAs without cancer. Reproductive health surveillance in female AYAs with cancer, especially those with breast cancer, leukemia and lymphoma, is important for optimizing the quality of life among cancer survivors. Further studies are needed to investigate the potential effects of thyroid cancer and melanoma on infertility, and to understand possible mechanisms.
HUMAN REPRODUCTION
(2021)
Article
Medicine, General & Internal
Carolyn Taylor, Paul McGale, Jake Probert, John Broggio, Jackie Charman, Sarah C. Darby, Amanda J. Kerr, Timothy Whelan, David J. Cutter, Gurdeep Mannu, David Dodwell
Summary: This study describes the long-term breast cancer mortality among women with a past diagnosis and estimates the absolute breast cancer mortality risks for patients with a recent diagnosis. The results show that the mortality rate is highest in the five years after diagnosis and then declines. The mortality rates and risks decrease with increasing calendar periods.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Article
Oncology
Justine M. Kahn, Frances B. Maguire, Qian Li, Renata Abrahao, Jamie E. Flerlage, Elysia Alvarez, Theresa H. M. Keegan
Summary: This study analyzed overall and HL-specific survival in a population-based cohort of 4807 HL patients younger than 40 years old in California from 2007 to 2017. The study found that older age and non-White race/ethnicity were associated with worse survival outcomes, even after adjusting for treatment data. Further research is needed to understand the factors contributing to disparities in survival among children and AYAs with HL.
Article
Oncology
Asa Akesson, Claudia Adok, Pernilla Dahm-Kahler
Summary: This study investigated the recurrences and survival of endometrioid endometrial cancer (EC) and found a low overall recurrence rate, with only a small portion of recurrences limited to the vaginal area, which had a better prognosis compared to other sites of recurrence. Age, FIGO stage, and adjuvant treatment were identified as independent prognostic factors for recurrence.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Medicine, General & Internal
Cathrine Fonnesbech Hjorth, Per Damkier, Bent Ejlertsen, Timothy Lash, Henrik Toft Sorensen, Deirdre Cronin-Fenton
Summary: This study aimed to investigate how socioeconomic position influences the effectiveness of cancer-directed treatment in premenopausal breast cancer patients, and found that patients with lower socioeconomic status had an increased risk of mortality, but not always recurrence.
Article
Oncology
Amy M. Berkman, Clark R. Andersen, Michelle A. T. Hildebrandt, J. A. Livingston, Adam L. Green, Vidya Puthenpura, Susan K. Peterson, Joel Milam, Kimberly A. Miller, David R. Freyer, Michael E. Roth
Summary: This study found that in addition to cancer type, sociodemographic factors such as age, race, socioeconomic status, and insurance status also contribute to the risk of early death in AYAs with cancer. Further research is needed to understand the interplay between cancer type, treatment, and health systems to address these disparities and improve outcomes for AYAs with cancer.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Alisha Kassam, Abha Gupta, Adam Rapoport, Amirrtha Srikanthan, Rinku Sutradhar, Jin Luo, Kimberley Widger, Joanne Wolfe, Craig Earle, Sumit Gupta
Summary: Evidence suggests that a significant proportion of adolescents and young adults with cancer receive high-intensity end-of-life care, but the involvement of palliative care physicians can help mitigate this risk.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Maya Schulpen, Bianca F. Goemans, Gertjan J. L. Kaspers, Marc H. G. P. Raaijmakers, C. Michel Zwaan, Henrike E. Karim-Kos
Summary: The study found that AYAs diagnosed with AML in the Netherlands had significantly lower survival rates compared to children, with a 60% higher risk of excess mortality for AYAs. Despite improvements in care over time, there still exists a substantial survival gap between the two age groups. However, early mortality rates did not differ between children and AYAs.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Chelsea L. Collins, Jiahao Peng, Sharn Singh, Ann S. Hamilton, David R. Freyer
Summary: Most AYAs aged 15 to 24 receive care from adult providers, but those with certain types of cancer are more likely to see pediatric providers. In general, there is no survival difference based on provider type.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2021)
Article
Oncology
Sumit Gupta, Rinku Sutradhar, Qing Li, Natalie Coburn
Summary: While AYA living in rural and remote areas had high rates of ESAS screening within a population-wide symptom assessment program, those in low-income urban areas were substantially less likely to be screened. Patients with hematologic malignancies had lower screening rates despite experiencing high symptom burdens. Interventions targeting AYA are necessary to improve screening uptake.
Article
Anesthesiology
Pin-Hung Yeh, Han-Wei Yeh, Shun-Fa Yang, Yu-Hsun Wang, Ming-Chih Chou, Ping-Kun Tsai, Chao-Bin Yeh
Summary: A retrospective cohort study was conducted to evaluate the relationship between postoperative opioid use and long-term surgical outcomes in patients with hepatocellular carcinoma (HCC). The study found that postoperative opioid use does not affect overall and recurrence-free survival in patients undergoing hepatectomy or liver transplantation for HCC.
Article
Oncology
Hallie Coltin, Adam Rapoport, Nancy N. Baxter, Chenthila Nagamuthu, Paul C. Nathan, Jason D. Pole, Franco Momoli, Sumit Gupta
Summary: Adolescents and young adults with cancer may receive high-intensity end-of-life care, with pediatric care and rural residence associated with higher odds of ICU death.
Article
Oncology
Jessica K. Sheth Bhutada, Amie E. Hwang, Lihua Liu, Kai-Ya Tsai, Dennis Deapen, David R. Freyer
Summary: Despite overall survival improvements for adolescents and young adults with cancer, certain subgroups such as non-Hispanic Blacks, males, and those with low socioeconomic status face increased risk of metastatic disease. Metastatic melanoma stands out for demonstrating multiple sociodemographic disparities. Future cancer-specific studies should investigate the connection between sociodemographic risk factors and biological drivers of metastases to inform targeted public health efforts.
Review
Oncology
Emily H. Yang, Harmonie B. Strohl, H. Irene Su
Summary: Fertility preservation is an important consideration for survivors of childhood, adolescent, and young adult cancer. It is recommended that fertility discussions and options be offered at diagnosis and after treatment. However, there is a need for further research and improvement in risk stratification and access to fertility preservation care.
Article
Oncology
Denise Riedel Lewis, Elizabeth J. Siembida, Nita L. Seibel, Ashley Wilder Smith, Angela B. Mariotto
Summary: This study analyzed long-term survival trends for cancer types with the highest mortality among AYA patients. Significant improvements in 5-year relative survival were found for some cancer types, while limited or no improvement was observed for others. The findings suggest the need for continued research focusing on specific cancer types with limited survival improvements.
Review
Public, Environmental & Occupational Health
Danny R. Youlden, Peter D. Baade, Andrew S. Moore, Jason D. Pole, Patricia C. Valery, Joanne F. Aitken
Summary: Survival for childhood cancer in Australia has continued to improve over recent decades, with most cancers showing improvements in survival. The study also estimated the number of deaths among Australian children that were potentially avoided due to improvements in survival.
PAEDIATRIC AND PERINATAL EPIDEMIOLOGY
(2023)
Article
Oncology
Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng
Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Substance Abuse
Dolly Baliunas, Coral Gartner, Samantha A. Hollingworth, Clair Sullivan, Tracy Comans, Jason D. Pole
Summary: There has been a differential change in the dispensing of subsidised smoking cessation medicines in Australia since the COVID-19 pandemic, with varenicline prescriptions largely stable and NRT patches being dispensed at a lower rate than expected.
DRUG AND ALCOHOL REVIEW
(2023)
Article
Oncology
Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Paul C. Nathan, Vijay Ramaswamy
Summary: This study characterized the late effects of childhood medulloblastoma survivors using real-world health services data. The findings reveal significant long-term medical sequelae and increased mortality rates, emphasizing the need for a re-evaluation of current treatment approaches and prioritization of interventions targeting late effects.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Angela Punnett, Nancy N. N. Baxter, David Hodgson, Rinku Sutradhar, Jason D. D. Pole, Cindy Lau, Paul C. C. Nathan, Sumit Gupta
Summary: We used population-based clinical and healthcare data to study the treatment patterns and long-term outcomes of adolescents and young adults (AYA) with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). We collected detailed clinical data of AYA aged 15-21 years at diagnosis with NLPHL in Ontario, Canada between 1992 and 2012. Additional events such as subsequent malignant neoplasms, relapses, and deaths were identified through linkage to healthcare databases. The study found that AYA with NLPHL have excellent long-term survival rates, and resection alone was associated with good outcomes, but strategies to avoid chemotherapy and radiation should be considered due to the risk of subsequent malignant neoplasms.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Oncology
Giancarlo Di Giuseppe, Lief Pagalan, Arif Jetha, Petros Pechlivanoglou, Jason D. Pole
Summary: The purpose of this study was to identify, evaluate, and summarize evidence on the educational attainment, employment status, and income of adolescents and young adults (AYAs) who survive cancer. A search was conducted in six databases for articles published between January 1, 2010, and March 31, 2022. Twelve articles met the inclusion criteria, which included AYA survivor population, quantitative design, and a cancer-free comparator group. The findings indicated that educational attainment was similar to that of cancer-free peers, but AYA survivors were more likely to be unemployed, have lower incomes, and require social security for income supplementation. Female gender, brain cancer diagnosis, and the presence of late-effects were identified as risk factors for severe outcomes. Limited socioeconomic evidence exists for AYAs surviving cancer, highlighting the need for further research.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Oncology
Catherine Mark, Paul Gibson, Lucie Lafay-Cousin, Georgina Martin, Sapna Oberoi, Lucie Pecheux, Shahrad R. Rassekh, Alexandra Zorzi, Sarah Alexander, Sumit Gupta
Summary: This retrospective study investigated the outcomes of 86 children with cancer who were diagnosed with COVID-19. 41.9% of the patients required hospitalization, but only 11.6% of hospitalizations were attributed to the virus. There were no deaths directly caused by COVID-19, and the findings support minimizing the interruption of chemotherapy after infection.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
(2023)
Review
Gastroenterology & Hepatology
Colin Sue-Chue-Lam, Matthew Castelo, Amina Benmessaoud, Teruko Kishibe, Diego Llovet, Christine Brezden-Masley, Amy Y. X. Yu, Jill Tinmouth, Nancy N. Baxter
Summary: A scoping review found limited research on non-pharmacological interventions to improve patient-reported outcomes of colonoscopy. There was significant variation in the characteristics and results of the included studies across different countries. Future research should focus on underinvestigated interventions and develop consensus-based guidelines for study design.
BMJ OPEN GASTROENTEROLOGY
(2023)
Review
Health Care Sciences & Services
Ben G. Glenwright, Joshua Simmich, Michelle Cottrell, Shaun P. O'Leary, Clair Sullivan, Jason D. Pole, Trevor Russell
Summary: This systematic literature review identifies factors influencing the implementation of ePROMs and ePREMs in healthcare settings. Results indicate that 96 code categories influence the implementation of ePROMs and ePREMs, providing an implementation checklist for clinicians, organizations, and policymakers.
JOURNAL OF PATIENT-REPORTED OUTCOMES
(2023)
Article
Oncology
Vicky R. Breakey, Rinku Sutradhar, Paul C. Nathan, Serina Patel, Laura Wheaton, Qing Li, Mylene Bassal, Paul Gibson, Jason D. Pole, Uma Athale, Sumit Gupta
Summary: Patient re-engagement with primary care physicians (PCPs) during and after treatment for acute lymphoblastic leukemia (ALL) is low. Involvement of PCPs during treatment can improve post-treatment engagement with PCPs among ALL survivors.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Priya Sayal, Sara Rizakos, Emily Lam, Julie Constantin, Catherine Diskin, Ute Bartels, Julia Orkin, Paul C. Nathan
Summary: This study aimed to explore the experience of parental caregivers caring for medulloblastoma survivors. The study found that parental caregivers face long-term challenges and personal and family impacts. The conclusion of this study is that further improvement is needed in care models and support systems for families with a child who has survived medulloblastoma.
PEDIATRIC BLOOD & CANCER
(2023)
Editorial Material
Oncology
Junious Sichali, Avi Denburg, Harriet Khofi, Cecilia Mdoka, Deborah Nyirenda, Yamikani Chimalizeni, George Chagaluka, Elizabeth Molyneux, Marc Y. R. Henrion, Sumit Gupta, Trijn Israels
PEDIATRIC BLOOD & CANCER
(2023)
Article
Pediatrics
Mohammad R. Alqudimat, Karine Toupin April, Lindsay Jibb, Charles Victor, Paul C. Nathan, Jennifer Stinson
Summary: This study aimed to test the inter-rater reliability, construct validity, and feasibility of the modified Which Health Approaches and Treatments Are You Using? (WHAT) questionnaires in pediatric oncology. The results showed strong inter-rater reliability and strong agreements between the modified WHAT and the diary. Significant relationships were found between recent and non-recent CHA users in relation to the easy access to CHA. The feasibility of the modified WHAT was also demonstrated.
Article
Oncology
Colin Sue-Chue-Lam, Christine Brezden-Masley, Rinku Sutradhar, Amy Y. X. Yu, Nancy N. Baxter
Summary: This study examined the association between the duration of oxaliplatin-containing adjuvant chemotherapy and mortality in stage III colon cancer. The results showed that compared to receiving a full course of treatment, patients who received only 50% of the course had slightly higher overall mortality and cancer-specific mortality, but the differences were not significant.